NCT03275285 2026-02-09
IKEMA
Sanofi
Phase 3 Completed
Clinical Trials
16 trialsNCT03180736 2025-12-19
EMN14
European Myeloma Network B.V.
Phase 3 Completed
NCT02252172 2025-10-20
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT03525678 2025-09-03
A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody
GlaxoSmithKline
Phase 2 Completed
NCT03548207 2025-07-30
CARTITUDE-1
Janssen Research & Development, LLC
Phase 1/2 Completed
NCT03361748 2025-05-23
KarMMa
Celgene
Phase 2 Completed
NCT03158688 2025-05-09
CANDOR
Amgen
Phase 3 Completed
NCT03277105 2025-04-29
A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT03412565 2025-04-29
A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
Janssen Research & Development, LLC
Phase 2 Completed
NCT01998971 2025-04-25
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Completed
NCT02541383 2025-04-13
Cassiopeia
Intergroupe Francophone du Myelome
Phase 3 Completed
NCT02990338 2025-01-17
ICARIA-MM
Sanofi
Phase 3 Completed
NCT03110562 2024-08-21
BOSTON
Karyopharm Therapeutics Inc
Phase 3 Completed
NCT02034110 2023-08-21
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Novartis
Phase 2 Completed
NCT02336815 2023-01-26
STORM
Karyopharm Therapeutics Inc
Phase 2 Completed
NCT02963493 2022-11-22
HORIZON
Oncopeptides AB
Phase 2 Completed